翰森制药（03692）发布公告，完成发行46.8亿港元于2033年到期的零息可换股债券。董事会宣布，认购协议所载发行债券的所有先决条件均已达成，且发行债券已于2026年2月3日成功落实。
债券预计将于2026年2月4日或前后获准于维也纳证券交易所上市及交易。所得款项预计净额约为46.4亿港元，其中约65%将用于药物研发及引进授权，包括支持抗肿瘤、中枢神经系统、代谢及自身免疫疾病领域的创新药物研发。
约25%将用于新建研发中心和生产线及升级现有设施，特别是位于上海浦东的全球研发总部项目的二期建设。约10%将用于营运资金及其他一般企业用途，包括支付员工薪酬和日常运营支出。债券所得款项净额预计将在2031年悉数动用。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.